Egalet (EGLT) shares are soaring in trading today following a positive vote from an FDA panel for the company's abuse-deterrent ARYMO ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The panel voted 18-1 to recommend approval of ARYMO ER; the FDA's final decision is scheduled for Oct. 14.